Literature DB >> 21412929

Genomic aberrations in diffuse low-grade gliomas.

Hanne-Sofie S Dahlback1, Ludmila Gorunova, Petter Brandal, David Scheie, Eirik Helseth, Torstein R Meling, Sverre Heim.   

Abstract

The current classification of diffuse low-grade gliomas is based mainly on histopathological criteria, which cannot accurately predict the highly variable clinical course observed in patients with such tumors. In an attempt to increase pathogenetic understanding of these tumors, we investigated 38 WHO Grade II astrocytomas, oligodendrogliomas, and oligoastrocytomas using a combination of G-band chromosome analysis and high-resolution comparative genomic hybridization (HR-CGH). Abnormal karyotypes were found in 41% of tumors. Karyotypes of astrocytomas and oligodendrogliomas were near-diploid whereas oligoastrocytomas also displayed near-tetraploid clones. The most common aberrations were losses of chromosomes X, Y, 3, 4, 6, and 11 and gains of chromosomes 8 and 12. The only recurrent structural rearrangement was del(6)(q21). HR-CGH analysis verified karyotyping findings but also revealed frequent losses at 1p, 17q, and 19q and gains of 7q, 10p, 11q, and 20p. Among the tumors were two gemistocytic astrocytomas, a subgroup of diffuse astrocytomas with a particular predisposition for progression but not studied cytogenetically before; one showed a near-diploid, complex karyotype with structural aberrations of chromosomes 1, 3, and 11 whereas both displayed simple aberrations including loss of 11p by HR-CGH. Our findings suggest that within diffuse low-grade gliomas are genetically distinct entities that do not fit the currently used classification. In addition, tumors with complex chromosomal aberrations had a higher tendency for aggressive tumor behavior (shorter progression-free survival) than tumors displaying simple aberrations only (P = 0.07). This could help identify genetic subsets of patients with low-grade glioma who might benefit from early antineoplastic therapy.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21412929     DOI: 10.1002/gcc.20866

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  7 in total

1.  Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas.

Authors:  Agustí Alentorn; Hinke F van Thuijl; Yannick Marie; Hussa Alshehhi; Catherine Carpentier; Blandine Boisselier; Florence Laigle-Donadey; Karima Mokhtari; Ilari Scheinin; Pieter Wesseling; Bauke Ylstra; Laurent Capelle; Khê Hoang-Xuan; Marc Sanson; Jean-Yves Delattre; Jaap C Reijneveld; Ahmed Idbaih
Journal:  Neuro Oncol       Date:  2013-12-12       Impact factor: 12.300

2.  Concomitant 1p/19q co-deletion and IDH1/2, ATRX, and TP53 mutations within a single clone of "dual-genotype" IDH-mutant infiltrating gliomas.

Authors:  Cinthya J Zepeda-Mendoza; Rachael A Vaubel; Shabnam Zarei; Cristiane M Ida; Martin Matthews; Sara Acree; Aditya Raghunathan; Caterina Giannini; Robert B Jenkins
Journal:  Acta Neuropathol       Date:  2020-03-13       Impact factor: 17.088

3.  Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies.

Authors:  Anna Luisa Di Stefano; Victor Enciso-Mora; Yannick Marie; Virginie Desestret; Marianne Labussière; Blandine Boisselier; Karima Mokhtari; Ahmed Idbaih; Khe Hoang-Xuan; Jean-Yves Delattre; Richard S Houlston; Marc Sanson
Journal:  Neuro Oncol       Date:  2012-11-16       Impact factor: 12.300

Review 4.  Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.

Authors:  Alexandra McAleenan; Hayley E Jones; Ashleigh Kernohan; Tomos Robinson; Lena Schmidt; Sarah Dawson; Claire Kelly; Emmelyn Spencer Leal; Claire L Faulkner; Abigail Palmer; Christopher Wragg; Sarah Jefferies; Sebastian Brandner; Luke Vale; Julian Pt Higgins; Kathreena M Kurian
Journal:  Cochrane Database Syst Rev       Date:  2022-03-02

5.  MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR.

Authors:  Annette Bentsen Håvik; Petter Brandal; Hilde Honne; Hanne-Sofie Spenning Dahlback; David Scheie; Merete Hektoen; Torstein Ragnar Meling; Eirik Helseth; Sverre Heim; Ragnhild A Lothe; Guro Elisabeth Lind
Journal:  J Transl Med       Date:  2012-03-06       Impact factor: 5.531

6.  DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.

Authors:  Adam Cohen; Mariko Sato; Kenneth Aldape; Clinton C Mason; Kristin Alfaro-Munoz; Lindsey Heathcock; Sarah T South; Lisa M Abegglen; Joshua D Schiffman; Howard Colman
Journal:  Acta Neuropathol Commun       Date:  2015-06-20       Impact factor: 7.801

Review 7.  Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta-analysis based on a Cochrane systematic review.

Authors:  Sebastian Brandner; Alexandra McAleenan; Hayley E Jones; Ashleigh Kernohan; Tomos Robinson; Lena Schmidt; Sarah Dawson; Claire Kelly; Emmelyn Spencer Leal; Claire L Faulkner; Abigail Palmer; Christopher Wragg; Sarah Jefferies; Luke Vale; Julian P T Higgins; Kathreena M Kurian
Journal:  Neuropathol Appl Neurobiol       Date:  2022-03-03       Impact factor: 6.250

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.